• Rejoni

  Participated · Series C · Jun 2026

  Rejoni is focused on developing and commercializing gynecological products built on proprietary biomaterials, with its lead investigational product the Juveena Hydrogel System. Juveena is designed to reduce the incidence and severity of intrauterine adhesions by placing a temporary hydrogel spacer in the uterine cavity using a proprietary transcervical catheter. The product is investigational and pending U.S. FDA approval and is not available for sale. Rejoni is clinical-stage and plans to scale manufacturing, supply operations, and market-access and physician/patient engagement in preparation for commercial launch. The company was founded in June 2020 in Bedford, MA; Amar Sawhney is founder and chairman and John Nealon is CEO. The recent $25 million financing will support these commercialization and regulatory preparations.

• Supira Medical

  Participated · Series E · Mar 2025

  Supira Medical, a Shifamed portfolio company based in Los Gatos, Calif., is developing the Supira System, an investigational next-generation pVAD intended for HRPCI and cardiogenic shock. The company recently completed enrollment of its U.S. SUPPORT I Early Feasibility Study, enrolling 15 patients across four clinical sites, and reports the Supira System has benefited 85 HRPCI patients to date. The device is investigational and not approved for sale in the U.S. or elsewhere. Supira plans to expand its clinical programs for both HRPCI and cardiogenic shock, including the SUPPORT II U.S. Pivotal Study for HRPCI that will be used to seek FDA PMA approval. The company aims to use new capital to accelerate those clinical programs and further validate its low-profile, high-flow technology platform. Supira Medical is advancing the Supira System, a percutaneous ventricular assist device (pVAD) featuring a novel low-profile, high continuous-flow design intended to provide full hemodynamic support initially for high-risk percutaneous coronary interventions and subsequently for cardiogenic shock. The system is built with a 10F profile to minimize vascular complications and incorporates multiple sensors for real-time pressure measurements. The Supira System is for investigational use only and is not for sale in the U.S. or outside the U.S. Supira is led by President and CEO Dr. Nitin Salunke and is a portfolio company of Shifamed, LLC. The company plans to expand its currently enrolling OUS studies, plan for U.S. studies, and prepare for a U.S. pivotal study submission. It raised $40M in Series D financing to support those clinical and regulatory activities. Supira Medical is developing a next-generation percutaneous ventricular assist device (pVAD) intended to provide temporary mechanical circulatory support for high-risk patients. The device is aimed for use during interventional procedures such as stent placement or angioplasty and to treat patients suffering from cardiogenic shock following severe heart attacks. The company is led by CEO Dr. Nitin Salunke and is a Shifamed portfolio company based in Los Gatos, CA. Supira plans to finalize product development and initiate a first-in-human clinical study for its pVAD. Financially, the company recently completed a financing round to support those activities. Supira Medical is focused on developing a next-generation percutaneous ventricular assist device (pVAD) for use in high-risk patients undergoing interventional procedures. The company was formed as the newest portfolio company of Shifamed and is located in Shifamed's facility in Silicon Valley. Jean Orth was appointed CEO in December 2017 and brings more than 25 years of cardiology-centric medical device experience. Supira closed a $15.5M financing that officially closed on April 25, 2018 to support its early development efforts. The round was led by The Capital Partnership with participation from Cormorant Asset Management and Shifamed Angels. Shifamed's incubator track record includes multiple exits, providing an experienced sponsor and potential exit pathways for its portfolio companies.

• Imperative Care

  Participated · Series E · Jul 2024

  Imperative Care is a commercial-stage medical technology company focused on advancing treatments for thromboembolic disease, including ischemic stroke and other vascular diseases caused by blood clots. Its commercially available product portfolio includes the Zoom Stroke System, the Symphony Thrombectomy System, and the Prodigy Thrombectomy System, which have been used in more than 78,000 procedures. The company is also developing the Telos endovascular robotic platform, currently in development and not approved for sale. Imperative Care said the $100 million convertible note financing will support commercialization of its existing stroke and vascular portfolios, next‑generation product development, and clinical evidence generation. The company is based in Campbell, Calif., and announced a new board appointment tied to the financing.

• Adona Medical

  Participated · Series C · Jul 2024

  Adona Medical is a pre-clinical medical technology company focused on solutions for advanced heart failure. It is developing an adjustable interatrial shunt with integrated bi-atrial pressure monitoring alongside remote patient monitoring components as part of a heart failure management platform. The platform is investigational and not approved for use in the U.S. or elsewhere. The company plans to use newly raised capital to further product development and to initiate clinical use of the adjustable interatrial shunt and monitoring capabilities. Adona Medical raised $33.5M in a Series C financing to support those plans. The company is a Los Gatos, CA–based Shifamed portfolio company led by CEO Brian Fahey. Adona Medical is a pre-clinical stage medical technology company developing a next-generation heart failure management platform. The company is led by CEO Brian Fahey and is a privately held portfolio company of Shifamed LLC. Its core work focuses on next-generation solutions for patients with advanced heart failure. Adona intends to use new funding to complete product development and to support further evaluation of its platform. The article does not provide operating metrics such as revenue or user counts. Adona is based in Campbell, California. Adona Medical focuses on advanced interventional approaches for heart failure. The company is a privately held portfolio company of medical innovation hub Shifamed LLC and is based in Campbell, CA. It raised $2.5M in seed financing to advance product development and expand its intellectual property portfolio. The round was funded exclusively by select Shifamed accredited angel investors. Leadership includes newly appointed CEO Brian Fahey and Chairman Amr Salahieh. Fahey joins Adona with over 15 years of medtech leadership and product development experience.

• Akura Medical

  Participated · Series B · Oct 2023

  Akura Medical is a Los Gatos-based medical technology company within the Shifamed portfolio that targets venous thromboembolism (VTE) treatment. Its flagship Katana™ Thrombectomy System uses high-velocity saline jets and embedded sensors to break up diverse clot types while providing real-time pulmonary artery pressure data during procedures. Complementing the hardware, the company is building NavIQ™, a CT-based quantification platform that creates 3D pulmonary vasculature models and offers clot characterization to aid pre-procedural planning. Together, the products aim to deliver more precise, data-driven thrombectomy and improve patient outcomes. Fresh capital will accelerate product development, finalize enrollment of the QUADRA-PE clinical study, and fund key regulatory submissions. Akura also intends to establish a joint venture in Qatar to expand its commercial footprint. To date, the company remains privately held and has not disclosed revenue or user metrics.

No current team members are available.